-
Je něco špatně v tomto záznamu ?
Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis
Jiri Minarik, Vlastimil Scudla, Marta Ordeltova, Tomas Pika, Jaroslav Bacovsky, Michael Steinbach, Vipin Kumar, Brian Van Ness
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu práce podpořená grantem
Grantová podpora
NR9489
MZ0
CEP - Centrální evidence projektů
NR9500
MZ0
CEP - Centrální evidence projektů
- MeSH
- analýza přežití MeSH
- apoptóza * MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie patologie MeSH
- plazmatické buňky * cytologie MeSH
- prognóza MeSH
- proliferace buněk * MeSH
- protinádorové látky terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI>3.0% and PC-AI<4.75%, and for good prognosis PC-PI<3.0% and PC-AI>4.75%. The median OS was 8 months vs 40 months, p=0.0002. Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone. Copyright 2010 Elsevier Ltd. All rights reserved.
Department of Computer Science and Engineering University of Minnesoty United States
Department of Genetics Cell Biology and Development University of Minnesoty United States
Department of Immunology University Hospital Olomouc Olomouc Czech Republic
Department of Internal Medicine 3 University Hospital Olomouc Olomouc Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14055245
- 003
- CZ-PrNML
- 005
- 20140724125044.0
- 007
- ta
- 008
- 140404s2011 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2010.04.015 $2 doi
- 035 __
- $a (PubMed)20488540
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Minařík, Jiří $7 xx0106330 $u Department of Internal Medicine III, University Hospital Olomouc, Olomouc, Czech Republic. abretina@email.cz
- 245 10
- $a Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis / $c Jiri Minarik, Vlastimil Scudla, Marta Ordeltova, Tomas Pika, Jaroslav Bacovsky, Michael Steinbach, Vipin Kumar, Brian Van Ness
- 520 9_
- $a We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI>3.0% and PC-AI<4.75%, and for good prognosis PC-PI<3.0% and PC-AI>4.75%. The median OS was 8 months vs 40 months, p=0.0002. Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone. Copyright 2010 Elsevier Ltd. All rights reserved.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a dospělí $7 D000328
- 650 02
- $a senioři $7 D000368
- 650 02
- $a senioři nad 80 let $7 D000369
- 650 02
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 12
- $a apoptóza $7 D017209
- 650 12
- $a proliferace buněk $7 D049109
- 650 02
- $a kohortové studie $7 D015331
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a lidé středního věku $7 D008875
- 650 02
- $a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101
- 650 12
- $a plazmatické buňky $x cytologie $7 D010950
- 650 02
- $a prognóza $7 D011379
- 650 02
- $a analýza přežití $7 D016019
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ščudla, Vlastimil, $d 1946- $7 jn20000402953 $u Department of Internal Medicine III, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Ordeltová, Marta $7 xx0100431 $u Department of Immunology, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Pika, Tomáš $7 xx0071238 $u Department of Internal Medicine III, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Bačovský, Jaroslav $7 xx0053311 $u Department of Internal Medicine III, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Steinbach, Michael $u Department of Computer Science and Engineering, University of Minnesoty, United States
- 700 1_
- $a Kumar, Vipin $u Department of Computer Science and Engineering, University of Minnesoty, United States
- 700 1_
- $a Van Ness, Brian $u Department of Genetics, Cell Biology and Development, University of Minnesoty, United States
- 773 0_
- $t Leukemia Research $g Roč. 35, č. 1 (2011), s. 44-48 $p Leuk Res $x 0145-2126 $w MED00003141
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20140404114123 $b ABA008
- 991 __
- $a 20140724125355 $b ABA008
- 999 __
- $a ok $b bmc $g 1018787 $s 853825
- BAS __
- $a 3
- BMC __
- $a 2011 $b 35 $c 1 $d 44-48 $x MED00003141 $i 0145-2126 $m Leukemia research $n Leuk Res
- GRA __
- $a NR9489 $p MZ0
- GRA __
- $a NR9500 $p MZ0
- LZP __
- $a NLK 2014-04/lpbo
